Aprea Therapeutics (APRE) Projected to Post Quarterly Earnings on Tuesday

Aprea Therapeutics (NASDAQ:APRE) will likely be releasing its Q4 2025 results before the market opens on Tuesday, March 24th. Analysts expect Aprea Therapeutics to post earnings of ($0.38) per share for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, March 27, 2026 at 9:30 AM ET.

Aprea Therapeutics (NASDAQ:APRE) last announced its earnings results on Monday, March 16th. The company reported ($0.32) EPS for the quarter. Aprea Therapeutics had a negative net margin of 2,666.46% and a negative return on equity of 88.12%. The business had revenue of $0.00 million for the quarter. On average, analysts expect Aprea Therapeutics to post $-3 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Aprea Therapeutics Stock Up 2.7%

Shares of APRE stock opened at $0.76 on Tuesday. The firm has a market capitalization of $5.29 million, a price-to-earnings ratio of -0.35 and a beta of 1.42. The stock has a fifty day moving average of $0.80 and a 200 day moving average of $1.11. Aprea Therapeutics has a 52 week low of $0.55 and a 52 week high of $2.65.

Institutional Trading of Aprea Therapeutics

An institutional investor recently bought a new position in Aprea Therapeutics stock. Jane Street Group LLC acquired a new stake in shares of Aprea Therapeutics, Inc. (NASDAQ:APRE) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 46,621 shares of the company’s stock, valued at approximately $40,000. Jane Street Group LLC owned approximately 0.67% of Aprea Therapeutics as of its most recent SEC filing. Institutional investors own 34.19% of the company’s stock.

Analysts Set New Price Targets

APRE has been the subject of several research reports. Weiss Ratings restated a “sell (e+)” rating on shares of Aprea Therapeutics in a report on Wednesday, January 21st. HC Wainwright reiterated a “buy” rating and set a $4.00 price target (down from $5.00) on shares of Aprea Therapeutics in a research report on Thursday, January 29th. Zacks Research raised shares of Aprea Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, February 16th. Finally, Wedbush lowered their price objective on shares of Aprea Therapeutics from $11.00 to $7.00 and set an “outperform” rating for the company in a report on Tuesday, February 10th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Aprea Therapeutics has an average rating of “Hold” and an average target price of $5.50.

About Aprea Therapeutics

Aprea Therapeutics is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies that restore tumor suppressor function in cancers driven by TP53 mutations. The company’s lead investigational agent, eprenetapopt (APR-246), is designed to convert mutant p53 protein into a form that induces programmed cell death in malignant cells. Aprea’s research focuses on hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as solid tumors harboring TP53 mutations.

Eprenetapopt has advanced through multiple clinical trials, including pivotal studies assessing its efficacy in combination with hypomethylating agents for patients with MDS.